A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq) in patient with patient with suspected cardiac amyloidosis
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Amyloidosis; Heart disorders
- Focus Diagnostic use
- Acronyms FLORAMICAR
Most Recent Events
- 10 Mar 2022 This trial has been completed in Italy according to European Clinical Trials Database record.
- 01 Jul 2019 New trial record